IL6 and neoplasm: Fearon and colleagues demonstrated that inflammation (IL-6) alters ketogenesis pathways in the liver, leading to glucocorticoid secretion, impaired anti-tumor immunity, and failure of immunotherapy (anti-PD-1/anti-PD-L1) [246].